In the Canakinumab Anti-Inflammatory Thrombosis Outcome Study, targeting IL-1β benefited patients with previous myocardial infarction (MI) in the view of non-fatal MI, non-fatal stroke, and cardiovascular death (26). Here, IL1B is linked to stroke disorder.